Biotechnology
Filter News
Found 10,331 articles
-
Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference
11/20/2018
Xencor, Inc. today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 10:30 a.m. ET in New York, NY.
-
Exelixis Announces Webcasts of Investor Conference Presentations in November 2018
11/20/2018
- Presentations to be webcast on www.exelixis.com -
-
Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
11/20/2018
Array BioPharma Inc. today announced that its Chief Executive Officer, Ron Squarer, will speak at the 30th Annual Piper Jaffray Healthcare Conference in New York.
-
Heron Therapeutics to Present at the 2018 Evercore ISI HealthCONx Conference
11/20/2018
Heron Therapeutics, Inc. announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, at 10:15 a.m. EST at the Boston Harbor Hotel.
-
SCYNEXIS, Inc. to Present at Upcoming November 2018 Investor Conferences
11/20/2018
SCYNEXIS, Inc. today announced that the Company will present at the following upcoming investor conferences
-
Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference
11/20/2018
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference, November 28, 2018
-
Revance to Participate in Upcoming Investor Conferences
11/20/2018
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.
-
Curis to Present at the 60th Annual Meeting of the American Society of Hematology
11/20/2018
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.
-
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
11/20/2018
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnership in viral Hepatitis.
-
BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company
11/20/2018
BioInvent International AB announced today that it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP compliant material to support their clinical development programs.
-
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
11/20/2018
Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).
-
Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018
11/20/2018
Three panels with 13 KOLs highlighting migraine, glutamate and inflammation platforms
-
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
11/20/2018
The study achieved its primary efficacy endpoint (p<0.0001)
-
Medical and Biotech Innovations Exposed at Future Tech Expo 2018
11/20/2018
Previously-unseen research to be revealed and explained
-
Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate $5.79 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing $1.78 million of Debt
11/20/2018
Tiziana Life Sciences plc today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares ("ADSs"), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares") at an initial public offering price of $9.90 per ADS, before underwriting discounts and commissions.
-
BioSpace Movers and Shakers for Nov. 19
11/19/2018
Companies bolstered their leadership with additions to boards of directors and c-suite offices. -
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.
-
It is estimated that 2.5 percent of all children in the U.S. might have a peanut allergy. Since 2010, according to the America College of Allergy, Asthma and Immunology, incidence of peanut allergies in children had risen 21 percent in the U.S.
-
Roivant Sciences and iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200
11/19/2018
- Roivant plans to initiate Phase 2 clinical trial in 2019
-
vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
11/19/2018
vTv Therapeutics Inc. today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City.